WEST CHESTER, Pa. – In 1990, the Hubble Telescope was launched and the World Wide Web was conceived, forever changing man’s interaction with science and each other. That same year, Chiral Technologies, Inc. (CTI) opened its doors as a corporation to do its part in transforming separation science by advancing innovative technology for enantioselective chromatography.

From the beginning, CTI’s goal was to serve life scientists as a trusted IND Enabler. The company’s chiral stationary phases (CSPs), columns and services play a vital role in drug discovery, helping pharmaceutical and biotech manufacturers go to market faster. That focus has remained through two decades, as CTI continues to produce the industry’s highest quality CSPs and columns for high performance liquid and supercritical fluid chromatography. CTI also provides advanced method development and outsourced separation services in its state-of-the-art laboratory in West Chester, Pa.

“After 20 years, we are still dedicated to our goal of enabling researchers to develop single-enantiomer products,” said Dieter Heckmann, President and CEO of Chiral Technologies, Inc. “We will continue to pave the way for future discoveries in life science.”

For more information about Chiral Technologies, Inc., visit www.chiraltech.com.

About Chiral Technologies Inc.

Chiral Technologies Inc. is the market leader in enantioselective chromatography. The company provides innovative solutions for research and development of chiral molecules. Chiral Technologies supplies bulk chiral stationary phases, and analytical and preparative chiral columns for chromatographic resolution of racemic mixtures into single enantiomers. Located in West Chester, Pa., the company operates an outsourcing center for custom separation of chiral intermediates and APIs on milligram to multi-kilogram scales for pre-clinical and clinical evaluation. Chiral Technologies has served the pharmaceutical and other life science industries since its founding in 1990. www.chiraltech.com